Clearly, future more in-depth studies are needed to define the clinical applications of FOXO3 inhibition by CBX in high-stage NB, in other “FOXO-resistant” cancers, or even in neurodegenerative diseases. This evidence concerns the gene FOXO3 and neurodegenerative disease.